Nimbus Therapeutics to Present Preclinical Rheumatoid Arthritis Data at ACR Convergence
Nimbus says selective SIK2 inhibitors reduced disease activity in a mouse model of rheumatoid arthritis. The company plans to present the preclinical data at ACR Convergence 2026.